CervoMed Inc. announced on July 9, 2026, that it has completed enrollment in its Phase 2a clinical study of neflamapimod for treating nonfluent variant primary progressive aphasia, a form of frontotemporal dementia. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.
